LOGIN  |  REGISTER
Terns Pharmaceuticals

Addus HomeCare to Participate in TD Cowen 45th Annual Health Care Conference

February 25, 2025 | Last Trade: US$111.03 0.00 0.00

FRISCO, Texas / Feb 25, 2025 / Business Wire / Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, today announced that Dirk Allison, Chairman and Chief Executive Officer and Brian Poff, Executive Vice President and Chief Financial Officer, will participate in the 45th Annual TD Cowen Health Care Conference from March 3-5 in Boston, MA.

In connection with the conference, there will be a live broadcast and replay of the Company’s presentation available under the Investor Relations section of the Company’s website, www.addus.com, starting at 11:50 a.m. Eastern Time / 10:50 a.m. Central Time on Tuesday, March 4, 2025. An online replay will also be available on the Company’s website for one month, beginning approximately one hour following the conclusion of the live broadcast.

About Addus HomeCare

Addus HomeCare is a provider of home care services that primarily include personal care services that assist with activities of daily living, as well as hospice and home health services. Addus HomeCare’s consumers are primarily persons who, without these services, are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. Addus HomeCare’s payor clients include federal, state, and local governmental agencies, managed care organizations, commercial insurers, and private individuals. Addus HomeCare currently provides home care services to approximately 62,000 consumers through 257 locations across 23 states. For more information, please visit www.addus.com.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page